Global COVID-19 Vaccines Market Research Report 2021-2022
Dublin, Oct. 28, 2021 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
According to the new updated study on COVID-19 Vaccines, approximately 53% of world population will be fully vaccinated by the end of the year 2021. This figure is expected to increase to 81% by the year 2022.
The rapid vaccination programmes launched around the world has led to millions of people being fully vaccinated, particularly in developed nations. With the rise in vaccination rates, measures designed to limit the spread of Covid-19 like mask mandates and capacity limits have been relaxed. The subsequent relaxation strengthened consumer confidence and allowed economic activity to return to normalcy. However, with the Covid-19 virus rapidly mutating, new variants have emerged in many parts of the world, posing a threat of potential future waves.
These new variants are more deadly than the original virus, more easily transmissible and can impact the effectiveness of vaccines. Viruses naturally change over time through the process of mutation. Among the thousands of variants currently circulating around the world, Delta (B.1.617.2), Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) have emerged as variants of concern, and the reason behind subsequent spike in infections.
These variants were first identified in India, the UK, South Africa, and Brazil respectively. The high number of Covid-19 cases also increases the risk of virus mutations, leading to the emergence of new variants. The spread of the Delta variant has forced some countries to step up their vaccination campaigns and bring back curbs on businesses, activity and travel.
Messenger RNA (mRNA)-based Covid-19 vaccine from Moderna and Pfizer stand out not only as frontrunners but also as being more protective against newer variants. mRNA vaccine although never been licensed for use in humans before, is now being approved in the fight against COVID-19 largely because of the speed at which these vaccines can be produced. mRNA vaccines work by introducing a part of mRNA that reacts to the viral protein.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
COVID-19 VACCINE DEVELOPMENT - A GLOBAL MARKET OVERVIEW
The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where Is The World Economy Headed in 2021?
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Dosing Interval Adjustment to Expand Coverage
Global COVID-19 Vaccine Inequity
Impact of Vaccine Inequity on the Labor Market
Emergency Use Approvals (EUAs) Dry Up in Developed Markets
Anti-Vaccine Movement Poses Significant Threat
THE VARIOUS COVID-19 VIRUS VARIANTS
Emergence of Delta Variant Sparks New Wave of Infections
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
Rising Cases in South Africa & Other Countries
California Strain Emerges to be more Contagious and Deadly
Is COVID-19 Virus Increasingly Resorting to Mutation to Outsmart Vaccines?
Less Effectiveness of AstraZeneca Vaccine Against South African Variant Leads to its Halt
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant
US Government Unveils Covid-19 Vaccine Booster Shot Plan to Maximize Vaccine Protection Against Emerging Variants
Pfizer/BioNTech Trailing a Booster Covid-19 Shot to Provide Variant Protection
Moderna's Variant-Specific Vaccine Candidate Ready for Clinical Study
AstraZeneca Plans to Adapt Covid-19 Vaccine against New Emerging Variants
Sinovac Vaccines Against Mutated Variants of Coronavirus to be Produced in 10 Weeks
AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
Roll-out Timeline of Select Frontrunners
COVID-19 Vaccine Approval Details
COVID-19 Vaccine Funding Details
Pfizer/BioNTech's COVID-19 Vaccine Receives World's First Authorization
UK Clinches the First Position in the World to Approve Pfizer's Vaccine
After UK, Pfizer's Vaccine Gains Approval from the US and EU
Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-19 Vaccine Production
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca's Vaccine - Third Globally to Obtain Approval
J&J's Single Shot Vaccination Resumes After Temporary Suspension
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson's Adenovirus-based COVID-19 Vaccine vis-a-vis Moderna or Pfizer
Russia Commences Mass Vaccination from Mid-December, 2020
Russia's Sputnik V Receives Approval for People Aged over 60
China Awards Conditional Approval to First COVID-19 Vaccine from Sinopharm
WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
China Issues License for Vaccine Production to Overseas Partners
Brazilian Authorities Approve Sinovac's CoronaVac
AstraZeneca's Covishield and Bharat Biotech's Covaxin Receive Emergency Use Approval in India
Sanofi Starts Trials of Second Vaccine on February 2021 after Disappointing Results of the First Vaccine
CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
Novavax Experiences Further Approval Delays To Produce Covid-19 Vaccine
Novavax Begins Crossover Arms for COVID-19 Vaccine Trials in UK and South Africa
mRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas
MARKET DYNAMICS
COVID-19 Vaccine Approvals Shift All Eyes toward Pre-Order and Distribution Statistics
Emergence of Novel Disease Variants Likely to Spell Need for Booster Shots
mRNA Vaccines Offer More Protection Against Newer Variants
Vaccine Companies Stress on Booster Dose
Pfizer-BioNTech COVID-19 Vaccine May Require Third Dose, Companies Seek Approval
J&J Vaccine May Need a Booster Dose
Longer Interval between the Two Doses of Pfizer Vaccine to Boost Antibody Levels
Mix and Match is the New COVID-19 Vaccine Mantra
Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
Vaccine Passports - The New Concept for Travel and Premises Access Permission
Vaccine Alliances Ensure Supplies for All
Licensing and Partnership Deals Worldwide Propel Vaccine Production
VACCINES FOR KIDS
Kids: A Key to COVID-19 Mitigation Efforts
Existent Covid-19 Vaccines for Children
Precautions to be taken by the Children infected with Covid-19
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021)
Pfizer Aims to Obtain Vaccine Approval for Kids Aged 5-11 Years by Fall, 2021
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on Children over Perceived Safety Concerns
COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17 in EU
REGIONAL MARKET PERSPECTIVE
FOCUS ON THE FRONTRUNNERS
Moderna, Inc. (USA)
Pfizer Inc./BioNTech (US/Germany)
AstraZeneca/University of Oxford (The UK)
Johnson & Johnson (USA)
CanSino Biologics, Inc. (China)
China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
Sinovac Biotech Ltd. (China)
Novavax, Inc. (USA)
Inovio Pharmaceuticals (USA)
Sanofi/GlaxoSmithKline (France/UK)
INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
The Most Extensive Vaccine Program in the History of Mankind Is Upon Us
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism to Hamper Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19 Vaccine
COVAX Inks Additional Deals for Global Rollout of COVID-19 Vaccines
African Countries Become Part of the COVAX Facility for Timely Access to Successful Vaccines
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments
KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Inactivated Vaccine Candidate in Preclinical Development: As on July 27, 2021
Protein-Subunit Vaccines
Protein-Subunit Vaccine Candidate in Preclinical Development: As on July 27, 2021
Non-Replicating Viral-Vector
Non-Replicating Viral Vector Vaccine in Preclinical Development: As on May 14th, 2021
Replicating Viral Vector Vaccine Candidate in Preclinical Development: As on May 14th, 2021
Nucleic Acid Vaccines
RNA Vaccine Candidate in Preclinical Studies: As on July 27, 2021
DNA Vaccine Candidate in Preclinical Studies: As on July 27, 2021
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Live Attenuated Virus Candidate in Preclinical Studies: As on July 27, 2021
Live Attenuated Bacterial Vector Candidate in Preclinical Studies: As on May 14th, 2021
Virus-like Particle Vaccines
Virus-like Particles (VLP) Vaccine Candidate in Preclinical Development: As on May 14th, 2021
WORLD COVID-19 VACCINE BRANDS
SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021
III. COMPETITION
Total Companies Profiled: 348
For more information about this report visit https://www.researchandmarkets.com/r/z5blvl
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900